Medtronic Hits Targets In 'Solid' Fiscal 2017
Executive Summary
Medtronic, medtech's No. 1 player, did not disappoint the market with its final fiscal quarter performance. With revenue and profit figures exceeding analysts' expectations, the group's outlook for fiscal 2018 is also looking equally positive.
You may also be interested in...
Cardiovascular Divisions Boost Medtronic's FYQ2 Top-Line As Hurricane Recovery Continues
Medtronic's revenue of $7.1bn for the second fiscal quarter of 2018 was down 4% year-over-year on an as-reported basis, but up 4% on a comparable constant-currency basis. –It would have been even greater if not for the hurricane that hindered manufacturing operations in Puerto Rico, the company reported Nov 21.
ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve
In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.